Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
10/10
Growth Score
2/10
Valuation Score
2/10
Momentum Score
9/10
₹30,368 Cr
126.29
14.4
45.38
0
12.06 %
--
0 %
82.86
9
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Suven Pharma
| 65.23 | 10.37 | 43.20 | 112.75 | 31.37 | -- | -- |
|
BSE Healthcare
| 38.74 | 1.81 | 17.79 | 53.60 | 18.58 | 28.78 | 11.84 |
|
BSE Mid Cap
| 31.28 | -1.40 | 4.22 | 49.54 | 24.23 | 28.35 | 17.66 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Suven Pharma
| 46.05 | 0.33 | 6.57 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
₹30,368.33 Cr
₹934.49 Cr
₹240.46 Cr
₹824.40 Cr
₹38.58 Cr
50.10%
High
₹541.00 - 1,287.90
₹1.00
25,45,64,956
NSE: SUVENPHAR, BSE: 543064
Mumbai, Maharashtra
www.suvenpharm.com
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients,... specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited. Read more
The total asset value of Suven Pharmaceuticals Ltd stood at ₹ 2,254 Cr as on 30-Jun-24
The share price of Suven Pharmaceuticals Ltd is ₹1,194.25 (NSE) and ₹1,192.95 (BSE) as of 03-Oct-2024 IST. Suven Pharmaceuticals Ltd has given a return of 31.37% in the last 3 years.
Suven Pharmaceuticals Ltd has a market capitalisation of ₹ 30,368 Cr as on 03-Oct-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Suven Pharmaceuticals Ltd is 14.40 times as on 03-Oct-2024, a 188% premium to its peers’ median range of 5.00 times.
The P/E ratio of Suven Pharmaceuticals Ltd is 126.29 times as on 03-Oct-2024, a 178% premium to its peers’ median range of 45.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Suven Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Suven Pharmaceuticals Ltd.
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
The promoter of Suven Pharmaceuticals Ltd is BERHYANDA LIMITED. BERHYANDA LIMITED owns 50.1 per cent of the total equity. The chairman of the company is Annaswamy Vaidheesh , and the managing director is V Prasada Raju..
There is no promoter pledging in Suven Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
47,550
|
|
|
35,631
|
|
|
29,577
|
|
|
25,312
|
| Suven Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.06
|
|
Operating margin(%)
|
27.94
|
|
Net Margin(%)
|
23.95
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Suven Pharmaceuticals Ltd was ₹240 Cr.
₹-8.40
